Kolelang

Colistimethate Sodium, the active ingredient in Kolelang, is a Polymyxin antibiotic presented as a formulation for inhalation use. It treats respiratory tract infections caused by susceptible Gram‑negative bacteria, notably Pseudomonas aeruginosa infections in patients with cystic fibrosis. The drug is administered via nebulisation to deliver the antibiotic directly to the lungs, improving local concentrations while limiting systemic exposure.

GNH USA supplies Kolelang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide.

Colistimethate Sodium is used to treat infections of the respiratory tract caused by Gram‑negative bacteria.

Respiratory tract infections caused by susceptible Gram‑negative bacteria: reduces bacterial load and improves lung function in affected patients. Cystic fibrosis lung disease due to Pseudomonas aeruginosa: helps control chronic infection and delay decline in pulmonary function. Bronchiectasis with chronic Pseudomonas infection: aids in managing persistent bacterial colonisation. Ventilator‑associated pneumonia caused by susceptible Gram‑negative organisms: provides targeted antimicrobial therapy via inhalation.

Common Side Effects: - Cough or throat irritation during inhalation. - Bronchospasm or wheezing after dosing. - Nausea or mild gastrointestinal upset. - Headache or dizziness. - Altered taste sensation. Serious or Rare Side Effects: - Acute respiratory distress or severe bronchospasm. - Anaphylactic or severe allergic reaction. - Hemoptysis (coughing up blood). - Nephrotoxicity with systemic absorption. - Hepatic dysfunction or elevated liver enzymes. - Neurological events such as seizures.

Before using Kolelang, consider the following precautions: - Renal function: monitor kidney parameters as colistin can be nephrotoxic. - Respiratory status: assess for bronchospasm and have bronchodilators available. - Allergy: avoid if there is a known hypersensitivity to polymyxins. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Concomitant nephrotoxic drugs: adjust dosing and increase monitoring. - Store at room temperature: keep in the original container, protect from moisture and light.

Colistimethate Sodium may interact with other medicines as follows: Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity. - Loop diuretics: heightened renal adverse effects. - Neuromuscular blocking agents: potential potentiation of respiratory depression. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor renal function. - Vancomycin: watch for additive nephrotoxic effects.